42 results on '"Visseren, F"'
Search Results
2. Impact of the stepwise approach to cardiovascular disease prevention in patients with established ASCVD from the 2021 ESC Prevention Guideline
3. Potential lifetime benefit of applying two-step ESC prevention strategy
4. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 59 trials
5. Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT
6. External validation of Systematic COronary Risk Evaluation 2 - Older Persons (SCORE2-OP) in the EPIC-Norfolk prospective population study
7. Performance of the Systematic COronary Risk Evaluation 2 (SCORE2) in the EPIC-Norfolk prospective population study
8. Effect of diet and lifestyle on the relationship between body mass index and waist circumference and cardiovascular mortality in myocardial infarction patients from the Alpha Omega Cohort
9. Patients with pseudoxanthoma elasticum (PXE) do not have dyslipidemia
10. Prediction of lifetime cardiovascular risk and individual lifetime treatment benefit in four European risk regions: geographic recalibration of the LIFE-CVD model
11. Inflammation and risk of recurrent cardiovascular events according to prior vascular disease location
12. Effect of evolocumab versus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
13. Cardiovascular mortality risk beyond 10 years in men and women; long-term follow-up from the EPIC-Norfolk prospective population study
14. The value of additional risk factors for improving 10-year cardiovascular risk prediction in apparently healthy people
15. Individual lifetime benefit from low-dose colchicine in chronic coronary artery disease patients
16. Quantity of adipose tissue and adipose tissue dysfunction and the risk of cancer in individuals at high risk of cardiovascular disease
17. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP
18. Patients with diffuse idiopathic skeletal hyperostosis have an increased burden of thoracic aortic calcifications
19. Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness
20. Detection of asymptomatic carotid stenosis in patients with lower-extremity arterial disease: development and external validations of a risk score
21. Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6
22. P1540Major adverse limb events (MALE) and the relation with classical risk factors in patients with symptomatic cardiovascular disease
23. P1819Screening for abdominal aortic aneurysm in patients with cardiovascular disease: yield of screening and AAA related-mortality during follow-up
24. 4943Remnant cholesterol increases the risk for recurrent vascular events independent of LDL-cholesterol in patients with clinical manifest vascular disease
25. 2180Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
26. 2153The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease; a cohort study
27. P3411Prevalence and risk factors of multifocal cardiovascular calcification in patients at high cardiovascular risk
28. P4990Heterogeneity of treatment effects from an intensive lifestyle weight loss intervention on cardiovascular events in patients with type 2 diabetes: data from the Look AHEAD trial
29. P646Effects of personalized therapy-effect predictions on statin treatment decisions by patients and physicians: a three-armed, blinded, randomized controlled trial
30. 1422Prevalence and characteristics of medication non-adherence assessed by quantitative liquid chromatography-tandem mass spectrometry in patients with hypertension
31. 5970Who to test for primary aldosteronism: development of a decision tool to select the right patients
32. P4388Treatment decisions based on individual estimated lifetime benefit versus individual estimated 10-year absolute risk reduction: a cost-effectiveness analyses with PCSK9 inhibition
33. 114Estimating individual cardiovascular disease risk reduction by blood pressure lowering in elderly patients: results from the HYVET study
34. 3141Predicting life-expectancy without recurrent vascular events in patients with cardiovascular disease: the REACH-SMART model
35. 1149Development and validation of a decision-support tool for individualizing lifelong lipid, blood-pressure, and aspirin treatment in people without cardiovascular disease
36. P1533Dealing with missing patient characteristics in clinical practice when using cardiovascular prediction models
37. P5084Added predictive value of follow-up blood-pressure measurements after alteration of therapy on cardiovascular risk in patients with hypertension
38. Cardiovascular and all-cause mortality in patients with intermittent claudication and critical limb ischaemia
39. Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects
40. Blood Pressure and Progression of Cerebral Atrophy in Patients With Vascular Disease
41. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases
42. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.